Mouse models as a translational platform for the development of new therapeutic agents in multiple Myeloma

Current Cancer Drug Targets

Volumn 12, Issue 7, 2012, Pages 814-822

  Tassone, P ^a,b   Neri, P ^a,c   Burger, R ^d   Di Martino, M T ^a   Leone, E ^a   Amodio, N ^a   Caraglia, M ^e   Tagliaferri, P ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b Temple University   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF KIEL   (Germany)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

5TMM; Microenvironment; Mouse models; Multiple myeloma; Scaffolds; SCID hu; SCID rab; SCID synth hu

Indexed keywords

ANTINEOPLASTIC AGENT; ATIPRIMOD; BHQ 880; MLN 120B; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL EXPANSION; ENGRAFTMENT; GENETIC ENGINEERING; GRAFT RECIPIENT; HUMAN; IMMUNOMODULATION; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; TRANSPLANTATION; TUMOR XENOGRAFT; TURKEY (BIRD);

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; MULTIPLE MYELOMA;

EID: 84866434864     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912802429292     Document Type: Article

References (87)

1. Palumbo, A.; Anderson, K. Multiple myeloma. N. Engl. J. Med. 2011, 364, 1046-1060.
2. Raab, M. S.; Podar, K.; Breitkreutz, I.; Richardson, P. G.; Anderson, K. C. Multiple myeloma. Lancet 2009, 374, 324-339.
3. Podar, K.; Tai, Y. T.; Hideshima, T.; Vallet, S.; Richardson, P. G.; Anderson, K. C. Emerging therapies for multiple myeloma. Expert Opin. Emerg. Drugs 2009, 14, 99-127.
4. Tassone, P.; Tagliaferri, P.; Rossi, M.; Gaspari, M.; Terracciano, R.; Venuta, S. Genetics and molecular profiling of multiple myeloma: novel tools for clinical management? Eur. J. Cancer 2006, 42, 1530-1538.
5. Chatterjee, M.; Chakraborty, T.; Tassone, P. Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy. Eur. J. Cancer 2006, 42, 1640-1652.
6. Podar, K.; Chauhan, D.; Anderson, K. C. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009, 23, 10-24.
7. Tassone, P.; Tagliaferri, P.; Fulciniti, M. T.; Di Martino, M. T.; Venuta, S. Novel therapeutic approaches based on the targeting of microenvironment-derived survival pathways in human cancer: experimental models and translational issues. Curr. Pharm. Des. 2007, 13, 487-496.
8. Anderson, K. C.; Carrasco, R. D. Pathogenesis of myeloma. Annu. Rev. Pathol. 2011, 6, 249-274.
9. Tassone, P.; Tagliaferri, P.; Rossi, M.; Calimeri, T.; Bulotta, A.; Abbruzzese, A.; Caraglia, M.; Neri, P. Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy. Curr. Cancer Drug Targets 2009, 9, 854-870.
10. Anderson, K. C. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp. Hematol. 2007, 35, 155-162.
11. Tassone, P.; Forciniti, S.; Galea, E.; Savino, R.; Turco, M. C.; Iacopino, P.; Tagliaferri, P.; Morrone, G.; Ciliberto, G.; Venuta, S. Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and Dexamethasone. Cell Death Differ. 2000, 7, 327-328.
12. Tassone, P.; Galea, E.; Forciniti, S.; Tagliaferri, P.; Venuta, S. The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. Int. J. Oncol. 2002, 21, 867-873.
13. Radl, J.; Hollander, C. F.; van den Berg, P.; de Glopper, E. Idiopathic paraproteinaemia. I. Studies in an animal model-the ageing C57BL/KaLwRij mouse. Clin. Exp. Immunol. 1978, 33, 395-402.
14. Radl, J. Age-related monoclonal gammapathies: clinical lessons from the aging C57BL mouse. Immunol. Today 1990, 11, 234-236.
15. Asosingh, K.; Radl, J.; van Riet, I.; van Camp, B.; Vanderkerken, K., The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol. J. 2000, 1, 351-356.
16. Garrett, I. R.; Dallas, S.; Radl, J.; Mundy, G. R. A murine model of human myeloma bone disease. Bone 1997, 20, 515-520.
17. Vanderkerken, K.; de Raeve, H.; Goes, E.; van Meirvenne, S.; Radl, J.; van Riet, I.; Thielemans, K.; van Camp, B. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br. J. Cancer 1997, 76, 451-460.
18. Vanderkerken, K.; Vande Broek, I.; Eizirik, D. L.; van Valckenborgh, E.; Asosingh, K.; van Riet, I.; van Camp, B. Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells. Clin. Exp. Metastasis 2002, 19, 87-90.
19. Menu, E.; de Leenheer, E.; de Raeve, H.; Coulton, L.; Imanishi, T.; Miyashita, K.; van Valckenborgh, E.; van Riet, I.; van Camp, B.; Horuk, R.; Croucher, P.; Vanderkerken, K. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin. Exp. Metastasis 2006, 23, 291-300.
20. Heath, D. J.; Vanderkerken, K.; Cheng, X.; Gallagher, O.; Prideaux, M.; Murali, R.; Croucher, P. I. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res. 2007, 67, 202-208.
21. Croucher, P. I.; de Hendrik, R.; Perry, M. J.; Hijzen, A.; Shipman, C. M.; Lippitt, J.; Green, J.; van Marck, E.; van Camp, B.; Vanderkerken, K. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J. Bone Miner. Res. 2003, 18, 482-492.
22. Henry, J. M.; Morley, A. A.; Sykes, P. J. Purging of myeloma cells using all-trans retinoic acid in a mouse model. Exp. Hematol. 2001, 29, 315-321.
23. Menu, E.; Jernberg-Wiklund, H.; Stromberg, T.; de Raeve, H.; Girnita, L.; Larsson, O.; Axelson, M.; Asosingh, K.; Nilsson, K.; van Camp, B.; Vanderkerken, K. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 2006, 107, 655-660.
24. Edwards, C. M.; Mueller, G.; Roelofs, A. J.; Chantry, A.; Perry, M.; Russell, R. G.; van Camp, B.; Guyon-Gellin, Y.; Niesor, E. J.; Bentzen, C. L.; Vanderkerken, K.; Croucher, P. I. Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo. Int. J. Cancer 2007, 120, 1657-1663.
25. Deleu, S.; Lemaire, M.; Arts, J.; Menu, E.; van Valckenborgh, E.; King, P.; vande Broek, I.; de Raeve, H.; van Camp, B.; Croucher, P.; Vanderkerken, K. The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models. Leukemia 2009, 23, 1894-1903.
26. Caers, J.; Menu, E.; de Raeve, H.; Lepage, D.; van Valckenborgh, E.; van Camp, B.; Alvarez, E.; Vanderkerken, K. Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma. Br. J. Cancer 2008, 98, 1966-1974.
27. Hansen, K.; Khanna, C. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur. J. Cancer 2004, 40, 858-880.
28. Bernardi, R.; Grisendi, S.; Pandolfi, P. P. Modelling haematopoietic malignancies in the mouse and therapeutical implications. Oncogene 2002, 21, 3445-3458.
29. Macor, P.; Secco, E.; Zorzet, S.; Tripodo, C.; Celeghini, C.; Tedesco, F. An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies. Curr. Pharm. Des. 2008, 14, 2023-2039.
30. Anderson, K. C.; Dalton, W. S. Synopsis of a research roundtable presented on cell signaling in myeloma: regulation of growth and apoptosis--opportunities for new drug discovery. Mol. Cancer Ther. 2002, 1, 1361-1365.
31. Kovalchuk, A. L.; Kim, J. S.; Park, S. S.; Coleman, A. E.; Ward, J. M.; Morse, H. C. 3rd; Kishimoto, T.; Potter, M.; Janz, S. IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc. Natl. Acad. Sci. USA 2002, 99, 1509-1514.
32. Lange, K.; Uckert, W.; Blankenstein, T.; Nadrowitz, R.; Bittner, C.; Renauld, J. C.; van Snick, J.; Feller, A. C.; Merz, H. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. Oncogene 2003, 22, 517-527.
33. Cheung, W. C.; Kim, J. S.; Linden, M.; Peng, L.; van Ness, B.; Polakiewicz, R. D.; Janz, S. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J. Clin. Invest. 2004, 113, 1763-1773.
34. Boylan, K. L.; Gosse, M. A.; Staggs, S. E.; Janz, S.; Grindle, S.; Kansas, G. S.; van Ness, B. G. A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma. Cancer Res. 2007, 67, 4069-4078.
35. Chesi, M.; Robbiani, D. F.; Sebag, M.; Chng, W. J.; Affer, M.; Tiedemann, R.; Valdez, R.; Palmer, S. E.; Haas, S. S.; Stewart, A. K.; Fonseca, R.; Kremer, R.; Cattoretti, G.; Bergsagel, P. L. AIDdependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008, 13, 167-180.
36. Chesi, M.; Matthews, G.M.; Garbitt, V.M.; Palmer, S.E.; Shortt, J.; Lefebure, M.; Stewart, A.K.; Johnstone, R.W.; Bergsagel, P.L. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 2012 Mar 26. [Epub ahead of print].
37. Carrasco, D. R.; Sukhdeo, K.; Protopopova, M.; Sinha, R.; Enos, M.; Carrasco, D. E.; Zheng, M.; Mani, M.; Henderson, J.; Pinkus, G. S.; Munshi, N.; Horner, J.; Ivanova, E. V.; Protopopov, A.; Anderson, K. C.; Tonon, G.; DePinho, R. A. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 2007, 11, 349-360.
38. Iwakoshi, N. N.; Lee, A. H.; Vallabhajosyula, P.; Otipoby, K. L.; Rajewsky, K.; Glimcher, L. H. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat. Immunol. 2003, 4, 321-329.
39. Morito, N.; Yoh, K.; Maeda, A.; Nakano, T.; Fujita, A.; Kusakabe, M.; Hamada, M.; Kudo, T.; Yamagata, K.; Takahashi, S. A novel transgenic mouse model of the human multiple myeloma chromosomal translocation t(14;16)(q32;q23). Cancer Res. 2011, 71, 339-348.
40. Hjorth-Hansen, H.; Seifert, M. F.; Borset, M.; Aarset, H.; Ostlie, A.; Sundan, A.; Waage, A. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J. Bone Miner Res. 1999, 14, 256-263.
41. Tsunenari, T.; Koishihara, Y.; Nakamura, A.; Moriya, M.; Ohkawa, H.; Goto, H.; Shimazaki, C.; Nakagawa, M.; Ohsugi, Y.; Kishimoto, T.; Akamatsu, K. New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor. Blood 1997, 90, 2437-2444.
42. Dewan, M. Z.; Watanabe, M.; Terashima, K.; Aoki, M.; Sata, T.; Honda, M.; Ito, M.; Yamaoka, S.; Watanabe, T.; Horie, R.; Yamamoto, N. Prompt tumor formation and maintenance of constitutive NF-kappaB activity of multiple myeloma cells in NOD/SCID/gammacnull mice. Cancer Sci. 2004, 95, 564-568.
43. Tassone, P.; Gozzini, A.; Goldmacher, V.; Shammas, M. A.; Whiteman, K. R.; Carrasco, D. R.; Li, C.; Allam, C. K.; Venuta, S.; Anderson, K. C.; Munshi, N. C. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res. 2004, 64, 4629-4636.
44. Hamasaki, M.; Hideshima, T.; Tassone, P.; Neri, P.; Ishitsuka, K.; Yasui, H.; Shiraishi, N.; Raje, N.; Kumar, S.; Picker, D. H.; Jacob, G. S.; Richardson, P. G.; Munshi, N. C.; Anderson, K. C. Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood 2005, 105, 4470-4476.
45. Neri, P.; Yasui, H.; Hideshima, T.; Tassone, P.; Raje, N.; Catley, L. P.; Ishitsuka, K.; Blotta, S.; Kiziltepe, T.; Ocio, E. M.; Fulciniti, M.; Kanekal, S.; Elliott, G. T.; Munshi, N. C.; Anderson, K. C. In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. Br. J. Haematol. 2006, 134, 37-44.
46. Neri, P.; Tagliaferri, P.; di Martino, M. T.; Calimeri, T.; Amodio, N.; Bulotta, A.; Ventura, M.; Eramo, P. O.; Viscomi, C.; Arbitrio, M.; Rossi, M.; Caraglia, M.; Munshi, N. C.; Anderson, K. C.; Tassone, P. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br. J. Haematol. 2008, 143, 520-531.
47. LeBlanc, R.; Catley, L. P.; Hideshima, T.; Lentzsch, S.; Mitsiades, C. S.; Mitsiades, N.; Neuberg, D.; Goloubeva, O.; Pien, C. S.; Adams, J.; Gupta, D.; Richardson, P. G.; Munshi, N. C.; Anderson, K. C. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002, 62, 4996-5000.
48. Lentzsch, S.; Rogers, M. S.; LeBlanc, R.; Birsner, A. E.; Shah, J. H.; Treston, A. M.; Anderson, K. C.; D'Amato, R. J. S-3-Aminophthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res. 2002, 62, 2300-2305.
49. Hideshima, T.; Catley, L.; Yasui, H.; Ishitsuka, K.; Raje, N.; Mitsiades, C.; Podar, K.; Munshi, N. C.; Chauhan, D.; Richardson, P. G.; Anderson, K. C. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006, 107, 4053-4062.
50. Trudel, S.; Stewart, A. K.; Li, Z.; Shu, Y.; Liang, S. B.; Trieu, Y.; Reece, D.; Paterson, J.; Wang, D.; Wen, X. Y. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin. Cancer Res. 2007, 13, 621-629.
51. Podar, K.; Tonon, G.; Sattler, M.; Tai, Y. T.; Legouill, S.; Yasui, H.; Ishitsuka, K.; Kumar, S.; Kumar, R.; Pandite, L. N.; Hideshima, T.; Chauhan, D.; Anderson, K. C. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc. Natl. Acad. Sci. USA 2006, 103, 19478-19483.
52. Suzuki, H.; Yasukawa, K.; Saito, T.; Goitsuka, R.; Hasegawa, A.; Ohsugi, Y.; Taga, T.; Kishimoto, T., Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo. Eur J Immunol 1992, 22, 1989-1993.
53. Neri, P.; Kumar, S.; Fulciniti, M. T.; Vallet, S.; Chhetri, S.; Mukherjee, S.; Tai, Y.; Chauhan, D.; Tassone, P.; Venuta, S.; Munshi, N. C.; Hideshima, T.; Anderson, K. C.; Raje, N. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin. Cancer Res. 2007, 13, 5903-5909.
54. Chauhan, D.; Hideshima, T.; Anderson, K. C. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br. J. Cancer 2006, 95, 961-965.
55. Coluccia, A. M.; Cirulli, T.; Neri, P.; Mangieri, D.; Colanardi, M. C.; Gnoni, A.; di Renzo, N.; Dammacco, F.; Tassone, P.; Ribatti, D.; Gambacorti-Passerini, C.; Vacca, A. Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood 2008, 112, 1346-1356.
56. Manni, S.; Brancalion, A.; Tubi, L.Q.; Colpo, A.; Pavan, L.; Cabrelle, A.; Ave, E.; Zaffino, F.; di Maira, G.; Ruzzene, M.; Adami, F.; Zambello, R.; Pitari, M.R.; Tassone, P.; Pinna, L.A.; Gurrieri, C.; Semenzato, G.; Piazza, F. Protein Kinase CK2 Protects Multiple Myeloma Cells from ER Stress-Induced Apoptosis and from the Cytotoxic Effect of HSP90 Inhibition through Regulation of the Unfolded Protein Response. Clin. Cancer Res. 2012, 18, 1888-1900.
57. Mitsiades, C. S.; Mitsiades, N. S.; Bronson, R. T.; Chauhan, D.; Munshi, N.; Treon, S. P.; Maxwell, C. A.; Pilarski, L.; Hideshima, T.; Hoffman, R. M.; Anderson, K. C. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res. 2003, 63, 6689-6696.
58. Dalton, W.; Anderson, K. C. Synopsis of a roundtable on validating novel therapeutics for multiple myeloma. Clin. Cancer Res. 2006, 12, 6603-6610.
59. Chauhan, D.; Neri, P.; Velankar, M.; Podar, K.; Hideshima, T.; Fulciniti, M.; Tassone, P.; Raje, N.; Mitsiades, C.; Mitsiades, N.; Richardson, P.; Zawel, L.; Tran, M.; Munshi, N.; Anderson, K. C. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood 2007, 109, 1220-1227.
60. Feo-Zuppardi, F. J.; Taylor, C. W.; Iwato, K.; Lopez, M. H.; Grogan, T. M.; Odeleye, A.; Hersh, E. M.; Salmon, S. E. Longterm engraftment of fresh human myeloma cells in SCID mice. Blood 1992, 80, 2843-2850.
61. Pilarski, L. M.; Hipperson, G.; Seeberger, K.; Pruski, E.; Coupland, R. W.; Belch, A. R. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 2000, 95, 1056-1065.
62. Pilarski, L. M.; Belch, A. R. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors. Clin. Cancer Res. 2002, 8, 3198-3204.
63. McCune, J. M.; Namikawa, R.; Kaneshima, H.; Shultz, L. D.; Lieberman, M.; Weissman, I. L. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 1988, 241, 1632-1639.
64. Kyoizumi, S.; Murray, L. J.; Namikawa, R. Preclinical analysis of cytokine therapy in the SCID-hu mouse. Blood 1993, 81, 1479-1488.
65. Akkina, R. K.; Rosenblatt, J. D.; Campbell, A. G.; Chen, I. S.; Zack, J. A. Modeling human lymphoid precursor cell gene therapy in the SCID-hu mouse. Blood 1994, 84, 1393-1398.
66. Namikawa, R.; Ueda, R.; Kyoizumi, S. Growth of human myeloid leukemias in the human marrow environment of SCID-hu mice. Blood 1993, 82, 2526-2536.
67. Tassone, P.; Neri, P.; Kutok, J. L.; Tournilhac, O.; Santos, D. D.; Hatjiharissi, E.; Munshi, V.; Venuta, S.; Anderson, K. C.; Treon, S. P.; Munshi, N. C. A SCID-hu in vivo model of human Waldenstrom macroglobulinemia. Blood 2005, 106, 1341-1345.
68. Wang, M.; Zhang, L.; Han, X.; Yang, J.; Qian, J.; Hong, S.; Lin, P.; Shi, Y.; Romaguera, J.; Kwak, L. W.; Yi, Q. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin. Cancer Res. 2008, 14, 2154-2160.
69. Urashima, M.; Chen, B. P.; Chen, S.; Pinkus, G. S.; Bronson, R. T.; Dedera, D. A.; Hoshi, Y.; Teoh, G.; Ogata, A.; Treon, S. P.; Chauhan, D.; Anderson, K. C. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 1997, 90, 754-765.
70. Yaccoby, S.; Barlogie, B.; Epstein, J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 1998, 92, 2908-2913.
71. Yaccoby, S.; Johnson, C. L.; Mahaffey, S. C.; Wezeman, M. J.; Barlogie, B.; Epstein, J. Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood 2002, 100, 4162-4168.
72. Burger, R.; Guenther, A.; Bakker, F.; Schmalzing, M.; Bernand, S.; Baum, W.; Duerr, B.; Hocke, G. M.; Steininger, H.; Gebhart, E.; Gramatzki, M. Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematol. J. 2001, 2, 42-53.
73. Tassone, P.; Neri, P.; Carrasco, D. R.; Burger, R.; Goldmacher, V. S.; Fram, R.; Munshi, V.; Shammas, M. A.; Catley, L.; Jacob, G. S.; Venuta, S.; Anderson, K. C.; Munshi, N. C. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 2005, 106, 713-716.
74. Tassone, P.; Neri, P.; Burger, R.; Savino, R.; Shammas, M.; Catley, L.; Podar, K.; Chauhan, D.; Masciari, S.; Gozzini, A.; Tagliaferri, P.; Venuta, S.; Munshi, N. C.; Anderson, K. C. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin. Cancer Res. 2005, 11, 4251-4258.
75. Fulciniti, M.; Hideshima, T.; Vermot-Desroches, C.; Pozzi, S.; Nanjappa, P.; Shen, Z.; Patel, N.; Smith, E. S.; Wang, W.; Prabhala, R.; Tai, Y. T.; Tassone, P.; Anderson, K. C.; Munshi, N. C. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin. Cancer Res. 2009, 15, 7144-7152.
76. Burger, R.; Le Gouill, S.; Tai, Y. T.; Shringarpure, R.; Tassone, P.; Neri, P.; Podar, K.; Catley, L.; Hideshima, T.; Chauhan, D.; Caulder, E.; Neilan, C. L.; Vaddi, K.; Li, J.; Gramatzki, M.; Fridman, J. S.; Anderson, K. C. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. Mol. Cancer Ther. 2009, 8, 26-35.
77. Li, J.; Favata, M.; Kelley, J. A.; Caulder, E.; Thomas, B.; Wen, X.; Sparks, R. B.; Arvanitis, A.; Rogers, J. D.; Combs, A. P.; Vaddi, K.; Solomon, K. A.; Scherle, P. A.; Newton, R.; Fridman, J. S. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokineand stromal cell support. Neoplasia 2010, 12, 28-38.
78. Neri, P.; Tassone, P.; Shammas, M.; Yasui, H.; Schipani, E.; Batchu, R. B.; Blotta, S.; Prabhala, R.; Catley, L.; Hamasaki, M.; Hideshima, T.; Chauhan, D.; Jacob, G. S.; Picker, D.; Venuta, S.; Anderson, K. C.; Munshi, N.C. Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma. Leukemia 2007, 21, 2519-2526.
79. Fulciniti, M.; Tassone, P.; Hideshima, T.; Vallet, S.; Nanjappa, P.; Ettenberg, S. A.; Shen, Z.; Patel, N.; Tai, Y. T.; Chauhan, D.; Mitsiades, C.; Prabhala, R.; Raje, N.; Anderson, K. C.; Stover, D. R.; Munshi, N. C. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009, 114, 371-379.
80. Tassone, P.; Goldmacher, V. S.; Neri, P.; Gozzini, A.; Shammas, M. A.; Whiteman, K. R.; Hylander-Gans, L.L.; Carrasco, D. R.; Hideshima, T.; Shringarpure, R.; Shi, J.; Allam, C. K.; Wijdenes, J.; Venuta, S.; Munshi, N. C.; Anderson, K. C. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 2004, 104, 3688-3696.
81. Hideshima, T.; Neri, P.; Tassone, P.; Yasui, H.; Ishitsuka, K.; Raje, N.; Chauhan, D.; Podar, K.; Mitsiades, C.; Dang, L.; Munshi, N.; Richardson, P.; Schenkein, D.; Anderson, K. C. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin. Cancer Res. 2006, 12, 5887-5894.
82. Shammas, M. A.; Koley, H.; Bertheau, R. C.; Neri, P.; Fulciniti, M.; Tassone, P.; Blotta, S.; Protopopov, A.; Mitsiades, C.; Batchu, R. B.; Anderson, K. C.; Chin, A.; Gryaznov, S.; Munshi, N. C. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia 2008, 22, 1410-1418.
83. Yata, K.; Yaccoby, S. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 2004, 18, 1891-1897.
84. Campbell, R. A.; Manyak, S. J.; Yang, H. H.; Sjak-Shie, N. N.; Chen, H.; Gui, D.; Popoviciu, L.; Wang, C.; Gordon, M.; Pang, S.; Bonavida, B.; Said, J.; Berenson, J. R. LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma. Int. J. Oncol. 2006, 28, 1409-1417.
85. Farnoushi, Y.; Cipok, M.; Kay, S.; Jan, H.; Ohana, A.; Naparstek, E.; Goldstein, R. S.; Deutsch, V. R. Rapid in vivo testing of drug response in multiple myeloma made possible by xenograft to turkey embryos. Br. J. Cancer 2011, 105, 1708-1718.
86. Calimeri, T.; Battista, E.; Conforti, F.; Neri, P.; di Martino, M. T.; Rossi, M.; Foresta, U.; Piro, E.; Ferrara, F.; Amorosi, A.; Bahlis, N.; Anderson, K. C.; Munshi, N.; Tagliaferri, P.; Causa, F.; Tassone, P. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primarymultiple myeloma cells. Leukemia 2011, 25,707-711.
87. DeWeerdt, S. Animal models: Towards a myeloma mouse. Nature 2011, 480, S38-S39.